The partnership with Croda International will allow Amyris to expand its market reach and increase access to its sustainable squalene. This could lead to increased revenue and market share for Amyris, as it will receive a share of profits generated from the sale of squalene excipients and formulated products incorporating its squalene technology for use in the vaccine field. Additionally, Amyris will receive an upfront payment of $4 million and a future performance-based milestone payment of $4 million.